iifl-logo

Supriya Lifescience Ltd Management Discussions

Add as a Preferred Source on Google
₹614.8
(-0.94%)
Nov 18, 2026|03:58:39 PM

Supriya Lifescience Ltd Share Price Management Discussions

GLOBAL ECONOMIC REVIEW

Overview

The global economy in 2025 evolved within a complex and increasingly uncertain macroeconomic environment, characterised by trade restrictions, policy uncertainty and persistent geopolitical tensions. Ongoing conflicts in Eastern Europe and the Middle East, including the Russia-Ukraine war, continued to disrupt global supply chains, energy markets and investor sentiment, resulting in periodic volatility in commodity prices and financial conditions. In addition, increasing tariffs, evolving trade arrangements, and geoeconomic fragmentation contributed to uncertainty around global trade flows and investments.

Despite these challenges, global economic activity remained resilient during the year, supported by stable labour markets, continued fiscal support and technology-led investments, particularly in artificial intelligence (AI). Economies also adapted through diversified trade routes, stronger energy security measures and supply chain realignment, supporting a relatively stable recovery. Consequently, global growth stood at 3.4% in 2025, compared to 3.3% in 2024.

Advanced economies expanded by 1.9% in CY 2025, supported by relatively stable labour markets, easing financial conditions and recovering demand, while emerging market and developing economies (EMDEs) grew by 4.4%, driven by resilient domestic consumption, improving manufacturing and services activity and continued infrastructure investment across key Asian economies.

Global headline inflation moderated to 4.1% in 2025, reflecting easing supply-side pressures and the impact of prior monetary tightening. However, inflation trends remained uneven across regions, with inflation above target in the United States while remaining relatively subdued in several other major economies.

Outlook

As 2026 unfolds, the global economy faces renewed uncertainty driven largely by escalating tensions in West Asia and disruptions across critical energy transit routes. Heightened risks around oil, LNG and fertiliser supplies have increased concerns over energy security, inflationary pressures and supply chain stability. Against this backdrop, global growth is projected to moderate to 3.1% in 2026 before improving marginally to 3.2% in 2027. However, improving diplomatic efforts, strategic energy diversification, and stronger regional cooperation are expected to gradually ease these pressures, supporting supply chain stability, moderating inflation, and fostering a balanced and resilient global economic recovery.

INDIAN ECONOMIC REVIEW

Overview

The Indian economy remained one of the fastest-growing major economies in FY 2025-26, supported by resilient domestic demand, infrastructure-led investment and policy reforms. According to the Second Advance Estimates released by the National Statistical Office (NSO), real GDP is estimated to grow by 7.6% in FY 2025-26, driven by strong private consumption and investment activity. The services sector remained the key growth driver, while manufacturing witnessed continued improvement supported by government-led production initiatives and infrastructure spending. Real GVA is estimated at Rs 294.40 lakh crore, reflecting growth of 7.7% over FY 2024-25.

India continues to remain among the worlds largest economies, currently ranking as the sixth-largest economy globally in nominal GDP terms as per the IMF. Structural reforms such as GST, Production Linked Incentive (PLI) schemes, and "Make in India 2.0" continue to improve formalisation, manufacturing competitiveness and ease of doing business, while strengthening Indias position within global supply chains. Manufacturing activity remained strong, with the HSBC India Manufacturing PMI rising to 54.7 in April 2026, supported by domestic demand and higher output levels.

The conflict in West Asia and disruptions across global trade routes have created fresh uncertainty around energy prices, logistics and availability of critical industrial inputs. As an import-dependent economy for crude oil and intermediate goods, India remains exposed to global supply chain disruptions and commodity price volatility. However, diversified sourcing strategies, domestic manufacturing capabilities and integration with emerging markets are helping mitigate external risks and support industrial continuity.

The governments large-scale investments, reforms and flagship initiatives, such as Make in India, Product-Linked Incentive (PLI) Schemes, have been instrumental in fostering industrial growth. The PLI scheme has attracted investments of approximately Rs 2.16 lakh across 14 key sectors, in line with the national goals like Atmanirbhar Bharat and Indias vision of a US$ 5 trillion economy.

Indias Index of Industrial Production (IIP) registered a growth of 4.1% in March 2026, supported by 4.3% growth in the Manufacturing sector and 5.5% growth in Mining activity, reflecting continued resilience in industrial and infrastructure-led economic activity.

Inflation moderated significantly during the year, with the RBI lowering its CPI inflation forecast for FY 2025-26 to 2.0%, supported by favourable supply conditions and easing food prices. In response, the RBI reduced the repo rate cumulatively to 5.25%, supporting credit availability and investment activity. Indias exports are projected to approach US$ 1 trillion in FY 2026-27, strengthened by trade agreements, manufacturing scale-up and improving export competitiveness.

The Indian Rupee (Rs) hit a record low of 97.15 against the U.S. Dollar (US$) on May 19, 2026. This historic depreciation was driven by surging global crude oil prices, rising U.S. Treasury yields, and heavy foreign capital outflows from domestic equity and bond markets.

Indias foreign exchange reserves stood at US688.9billionfortheweekendedMay15.ThismarkedadeclineofUS688.9billionfortheweekendedMay15.ThismarkedadeclineofUS 8.1 billion, largely pressured by rising tensions in West Asia, which have weighed on the rupee and overall emerging market sentiment.

India has reached a significant milestone in its economic development, with gross foreign direct investment (FDI) inflows totalling an impressive US$ 1.14 billion. The rise highlights a sharp 22% year-on-year expansion in rupee terms, reflecting continued strength in foreign investment activity and confidence in Indias growth trajectory.

Growth of the Indian economy

FY 23 FY 24 FY 25 FY 26
Real GDP Growth (%) 7.2 9.2 6.5 7.6

Growth of the Indian economy quarter by quarter, 2025-26

Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26
Real GDP Growth (%) 6.7% 8.4% 7.8% 7.3%

The banking sector continued to strengthen with gross Non-performing Assets (NPAs) of Scheduled Commercial Banks (SCBs) for domestic operations reaching a historic low of 2.15% as of September 2025. The capital-to-risk-weighted-asset ratio (CRAR) of the SCBs remained strong at 17.2 per cent as of September 2025, boosting banks profitability and credit growth.

Indias overall exports, merchandise and services combined, increased by 13.59% year-on-year to US 80.80 billion in April 2026, from US80.80 billion in April 2026, from US 71.13 billion in April 2025. Merchandise exports rose from US38.28billiontoUS38.28billiontoUS 43.56 billion, while services exports increased from US32.85billiontoUS32.85billiontoUS 37.24 billion. The surge is likely to be bolstered owing to the reduction of the US tariff on Indian products from 50% to 18%.

Indias gross GST collection reached Rs 22.27 lakh crore in FY 2025-26, registering an annual growth of 8.3% over FY 2024-25, reflecting strong economic activity and improved tax compliance.

The share of Private Final Consumption Expenditure (PFCE) in GDP increased to 61.5% in FY 2025-26, reflecting strong and broad-based consumption demand supported by low inflation, stable employment conditions, and rising real purchasing power. Consumption growth was further driven by resilient rural demand backed by strong agricultural performance and improving urban consumption aided by the rationalisation of direct and indirect taxes.

Indian equity markets remained resilient in 2026 despite global volatility. The NIFTY 50 closed at 23,659, while the BSE Sensex closed at 75,318.39, reflecting sustained investor confidence, domestic macroeconomic fundamentals, and optimism regarding Indias growth prospects.

The Indian mutual fund industrys Assets Under Management (AUM) rose to a record Rs 81.92 lakh crore, while monthly SIP contributions stood at Rs 31,115 crore. Equity mutual funds recorded inflows of Rs 38,440 crore during the month.

Foreign Portfolio Investors remained cautious amid rising global yields and geopolitical uncertainties, leading to nearly US$ 23 billion in outflows from Indian equities in 2026.

(Source: Reuters, Trading economics, IBEF, PIB, Gst.gov.in, PIB, Trading economics, Trading economics, MOSPI, RBI, PIB, Fortuneindia, AMFI India, Reuters)

Outlook

Indias GDP growth for FY26 is estimated at 7.4%, driven by the double engine of consumption and investment. It reaffirms Indias status as the fastest-growing major economy for the fourth consecutive year. The nation is expected to reach a US$ 30-35 trillion economy by 2047, entering the league of developed nations. Structural reforms and sustained growth momentum are driving this rapid progress, while digital and physical infrastructure are also expanding significantly.

Union Budget 2026-2027: Indias Union Budget FY 2026-27 emphasises public investment by raising the capital expenditure (capex) outlay to a record Rs 12.2 lakh crore. This nearly 9% increase from the previous years estimate of Rs 11.2 lakh crore is intended to sustain economic momentum and fulfil the governments "Viksit Bharat" vision for a developed India. Capital expenditure is prioritised in the budget, with allocations directed towards roads, railways, ports, airports, power transmission and urban infrastructure.

Free-Trade Agreement: The India-European Union (EU) Free Trade Agreement (FTA) improves market access for Indian exports by reducing tariffs and non-tariff barriers in sectors such as goods, chemicals, pharmaceuticals and IT-enabled services. This trade deal is likely to enhance Indias trade competitiveness, foreign direct investment (FDI) and export diversification. Similarly, India and the US have announced an interim trade framework, which is expected to provide tariff relief and US market access to India. This agreement may enhance Indian exports through supply chain integration with the US, while safeguarding domestic sectors such as agriculture.

Impact of Pay Commission: The 8th Pay Commission is projected to significantly impact the Indian economy by boosting consumer spending for over 1.1 crore employees and pensioners, driving growth in sectors like retail, automobile, and housing. Beyond individual pay packets, the changes are also expected to have a wider impact on the economy, especially on consumption, savings and government spending.

Monsoon: A favourable, well-distributed monsoon in 2026 is projected to boost agricultural output, stabilise food inflation, and potentially enable the RBI to cut interest rates, benefiting sectors like FMCG, automobiles, and banking.

Rate Cuts: The Reserve Bank of Indias Monetary Policy Committee projected CPI inflation at 4.6% for FY27, reflecting a balanced inflation outlook amid evolving domestic and global macroeconomic risks. In the backdrop of evolving macroeconomic and financial developments, the RBI has reduced the policy repo rate by 25 basis points to 5.25% with a neutral stance. It signals a growth inflation balance, owing to a benign inflation outlook on both the headline and core levels, that continues to provide the policy space to support the growth.

GLOBAL PHARMACEUTICAL INDUSTRY

The global pharmaceuticals market continues to witness strong growth momentum, driven by rising healthcare expenditure, increasing prevalence of chronic diseases, and accelerated digital transformation in drug development following the COVID-19 pandemic. The global pharmaceuticals market was valued at US 1,999.24 billion in 2025 and is projected to grow to US 1,999.24 billion in2025andisprojectedtogrowtoUS 4,035.35 billion by 2034, registering a CAGR of 8.19%, reflecting sustained global demand for innovative therapies, vaccines, and advanced healthcare solutions. North America dominated the pharmaceuticals market with a market share of 44.81% in 2026. Oncology drugs represent the largest and fastest-growing therapeutic market in the pharmaceutical industry, with global sales accounting for 17.62% market share in 2026.

The global pharmaceutical market is witnessing significant growth, driven by increasing demand for innovations and technologies in the healthcare sector, and rising cases of various chronic and life-threatening diseases. The growth during the projected period is reinforced by government policies, improved healthcare access, and higher investment.

Global growth in medical use is population-driven and is projected to increase at a 2.7% CAGR, unadjusted for population. Additionally, global medicine spending is expected to exceed US$ 2.6 trillion by 2030 and increase at a rate of 5-8% per year. Key drivers of growth include contributions from new products and the impact of patent expiries, particularly the growing role of biosimilars.

Source: (Fortune businessinsights, Iqvia)

GLOBAL API INDUSTRY

The global active pharmaceutical ingredient (API) market size was US 245.26 billion in 2025 and is projected to grow from US245.26 billion in 2025 and is projected to grow from US 261.28 billion in 2026 to US$ 457.75 billion by 2034 at a CAGR of 7.26% over the forecast period.

In pharmaceutical formulations, active pharmaceutical ingredients (API) constitute the fundamental therapeutic effect. Derived through chemical synthesis or natural extractions, API forms the core of the global drug manufacturing ecosystem. As the industry is shifting towards advanced therapeutics, precision medicine and innovative delivery platforms, demand for specialised APIs is expected to rise steadily.

Over the past two decades, the pharmaceutical supply chain has undergone a significant transformation, driven by globalisation and increased dependence on contract manufacturers. API outsourcing is emerging as a common strategy among pharmaceutical companies to optimise cost, scalability and operational efficiency. This approach is relevant for emerging biopharmaceutical and virtual pharma companies, relying on third-party manufacturers.

During Covid-19 pandemic, this globally dispersed framework showed inherent vulnerabilities. Logistical disruptions, restricted mobility, raw material shortages, and regular hurdles impacted supply continuity. Heightened regulations and compliance further caused production and approval delays. Going forward, the industry is increasingly focussed on improving supply chain resilience, regulatory agility and broader manufacturing base.

INDIAN PHARMACEUTICAL INDUSTRY

The Indian pharmaceutical industry continues to play an important role in both domestic healthcare and global medicine supply. India ranks third globally by volume and eleventh by value, supported by more than 3,000 pharmaceutical companies and over 10,500 manufacturing units. The sector remains one of the largest suppliers of generic medicines globally, contributing nearly 20% of global generic drug supply and manufacturing around 60,000 generic brands across 60 therapeutic categories.

The Indian pharmaceutical market was valued at US$ 57.61 billion in 2025 and is estimated to reach US$ 60.32 billion in 2026. It is projected to grow to US$ 79.74 billion by 2031 at a CAGR of 5.74% during 2026-2031. Growth is being supported by rising chronic disease burden, patent expiries that expand the generic pipeline, and government initiatives such as the Production Linked Incentive (PLI) scheme for strengthening domestic API manufacturing.

Prescription drugs accounted for 61.26% of total revenue in 2025, while anti-infectives remained the largest therapy segment with a 34.11% share. Oncology is expected to be the fastest-growing segment with a CAGR of 8.22% through 2031. Retail pharmacies continued to dominate distribution with a 64.57% share, while online pharmacies are expected to grow faster with increasing digital healthcare adoption.

Pharmaceutical exports also remained strong, reaching US$ 30.5 billion in FY 2024-25, with supplies to 191 countries. Exports in January 2026 increased to US$ 2.66 billion from US$ 2.59 billion in January 2025. With strong manufacturing capacity, export growth and policy support, the industry outlook remains positive for the coming years.

Indias pharmaceutical exports are projected to grow from approximately US$ 27 billion in 2023 to US$ 65 billion by 2030 and further to nearly US$ 350 billion by 2047. This growth will be driven by stronger global demand, expansion into regulated markets and competitiveness in complex therapies. India currently ranks 11th globally in export value, and the industry aims to move into the top five pharmaceutical exporters by 2047.

Innovation, regulatory compliance, quality standards and supply chain resilience will be critical for long-term growth. Greater investment in research, manufacturing excellence and domestic API capacity will support this transition. Collaboration between government and industry will also remain important in improving market access and strengthening Indias position as a global pharmaceutical manufacturing and export hub. Overall, the industry is likely to shift from scale-driven growth to value-led expansion.

(Source: PIB, Mordorintelligence, IPA)

INDIAN API INDUSTRY OVERVIEW

Active Pharmaceutical Ingredients (API) remain a vital segment within the pharmaceutical sector. The API market, currently valued at approximately US$ 15-16 billion, is expected to grow at a CAGR of 5-7% during FY27 and FY28. This growth is expected to be driven by favourable government policies, increasing demand for high-potency and complex APIs, rising domestic consumption, and expanding penetration into regulated and emerging global markets.

The Indian API sector has emerged as an attractive investment destination, supported by domestic demand, chemical manufacturing ecosystem, skilled workforce and adherence to international quality standards. Additionally, setting up and operating a modern manufacturing facility in India is estimated to cost nearly 40% less than in Western markets, improving its competitiveness.

Concurrently, rising geopolitical tensions between Western nations and China have prompted global pharmaceutical companies to diversify their sourcing hubs. Owing to this shift, India is positioned as a credible alternative for bulk drugs and APIs.

(Source: CareEdge)

Union budget allocation

The Department of Pharmaceuticals (DoP) may get an allocation of around Rs 1,100 crore for two new schemes announced in the Union Budget 2026-27. An increased allocation for the production-linked incentive (PLI) schemes of around Rs 2,499.84 crore during FY26-27 is also announced, which is around 2.2% higher than the Rs 2,444.93 crore allocated in FY 2025-26. The Union Budget 2026-27 proposes to allocate Rs 5,931.22 crore for the DoP, around a 12.6% increase compared to the Rs 5,268.72 crore allocated under the Budget Estimate (BE) for the fiscal 2025-26. Additionally, this budget proposed the Biopharma SHAKTI with an outlay of Rs 10,000 crore over five years, aimed at strengthening Indias ecosystem to produce biologics and biosimilars. PLI scheme for bulk drugs has been allocated Rs 66.40 crore in the budget to reduce import dependence and promote indigenous production of critical raw materials, including fermentation-based products like Penicillin G. Medical Devices Industry (SMDI) has an allocation of Rs 124.17 crore during 2026-27, encouraging indigenous production of advanced medical equipment such as MRI systems and cardiac implants. Promotion of Bulk Drug Parks is also implemented, with a budgetary outlay of Rs 3,000 crore, under which three bulk drug parks are approved and at developing stages in Andhra Pradesh, Gujarat and Himachal Pradesh, through their respective state implementing agencies. These initiatives aim to improve cost efficiency and supply chain resilience.

GROWTH DRIVERS FOR THE INDIAN PHARMACEUTICAL MARKET

Cost-efficient Manufacturing and R&D: India remains a global manufacturing hub for the pharmaceutical industry, supported by its lower manufacturing and research and development (R&D) costs. Cost advantages, combined with scale efficiencies and process expertise, enhance its competitiveness across generics, APIs, and specialty products. Additionally, India boasts the highest number of US Food and Drug Administration (USFDA)-approved manufacturing facilities outside the United States, with estimates ranging from over 650 to over 800+ compliant plants.

Government Support: The Make in India campaign, along with PLI schemes for API/KSM (Active Pharmaceutical Ingredients/Key Starting Materials) manufacturing, bulk drug parks and increased investment, reduces import dependency and fosters domestic production. The Union Budget 2026-27 marks a significant milestone in the Governments ongoing efforts to strengthen Indias healthcare system, with substantially enhanced allocation for the Ministry of Health & Family Welfare to Rs 1,06,530.42 crore, reflecting an increase of nearly 10% over the Revised Estimates of FY 2025-26. Indias strong economic growth further drives disposable income, which in turn is translated into higher healthcare expenditure and pharmaceutical demand. Owing to improved affordability, increased health awareness, and greater access to medical services, consumption is increasing.

Increasing Chronic Diseases: A prevalence of lifestyle-related diseases (cardiac, diabetes) drives the need for domestic consumption, complemented by a growing demand for affordable generics.

Ageing Population: By 2061, nearly one in four Indians is expected to be over 60 years of age, increasing the chances of chronic and age-related diseases. This demographic shift will elevate demand for long-term healthcare and pharmaceuticals. Balancing rising healthcare demand with cost pressure will be essential to preserve affordability and sustainability.

Outsourcing: Contract manufacturing remains a key growth driver in Indias pharmaceutical industry. Global pharmaceutical companies of the advanced markets are increasingly outsourcing production to India to leverage cost efficiencies, skilled manpower, and manufacturing capabilities.

COMPANY OVERVIEW

Since its inception in 2008, Supriya Lifescience Limited has remained an established API manufacturer with a portfolio spanning multiple therapeutic categories such as antihistamines, anti-allergics, vitamins, anaesthetics, and anti-asthmatics. With its presence in over 120 countries and a diversified portfolio of more than 38 APIs, the Company serves a broad global clientele. It continues to prioritise developing quality APIs and intermediates, catering to both innovator and generic markets.

During FY 2025-26, the Company launched a cardiovascular API, an ADHD product, a liquid anaesthetic. Ambernath FDF facility (tablets, capsules, liquids, sterile forms) ready for commissioning in H2 FY26. Lote Parshuram facilitys reactor capacity is increased by 55% with the commissioning of Module E, supporting future utilisation and margin resilience. The Company further reinforced sustainability through a new treatment plant and IGBC Gold-certified labs while expanding R&D capabilities across two centres with a target of 3 to 4 launches every year. It also added a Kilolab for high-value APIs.

Product-wise performance

Analgesic: During the year under review, the company reported 28.14 crore in this segment, by 3.5 y-o-y.

Anti-histamine: During the year under review, the company reported 76.13 crore in this segment, by 9.5% y-o-y.

Vitamins: During the year under review, the company reported 98.52 crore in this segment, by 12.3% y-o-y.

Anti-asthmatic: During the year under review, the company reported 46.15 crore in this segment, by 5.7% y-o-y.

Anti-allergic: During the year under review, the company reported 29.12 crore in this segment, growing by 3.6% y-o-y.

Outlook

Supriya Lifesciences outlook is centred on scaling operations and market presence. The 10-year CMO contract with a European pharma company is projected to contribute Rs 600 million every year from FY27, improving long-term visibility. With sustained investments in R&D, backward integration, and sustainability initiatives, Supriya is positioning itself for robust expansion across North America, Japan, Australia, and other regulated markets.

FINANCIAL OVERVIEW

Analysis of the profit and loss statement

Revenues: Revenues from operations reported a 18.97% growth from Rs 696 crore in 2024-25 to Rs 828 crore in 2025-26. Other Income of the company reported an increase by 17.04% as compared to FY 2024-25 and accounted for a 1.37% share of the companys revenues, reflecting the companys dependence on its core business operations.

Expenses: Total expenses increased by 22.52% in 2025-26 from Rs 435.69 crore in 2024-25 to Rs 533.83 crore due to business growth and inflation. Raw material costs, accounting for a 32.02% share of the companys revenues, increased by 14.06% due to changes in the product and region mix. Employee expenses, accounting for an 11.68% share of the companys revenues, increased by 20.07% from Rs 80.52 crore in 2024-25 to Rs 96.68 crore in 2025-26 due to additions and increments.

Analysis of the Balance Sheet

Sources of funds: The capital employed by the company increased 19.99% from Rs 1,030.12 crore as on March 31, 2025, to Rs 1,236.06 crore as on March 31, 2026, due to profits. Return on capital employed, a measurement of returns derived from every rupee invested in the business, decreased by 190 basis points from 24.28% in 2024-25 to 22.38% in 2025-26. The Company achieved growth in profitability during the year, although the increase in capital employed was relatively higher, resulting in a moderation of ROCE compared to the previous year. The net worth of the company increased 20.16% from Rs 996.76 crore as on March 31, 2025, to Rs 1,197.73 crore as on March 31, 2026, owing to the current years profit. As of March 31, 2026, the company has no long-term debt, except for lease liability. Finance costs of the company increased by 12.03% from Rs 1.69 crore in 2024-25 to Rs 1.89 crore in 2025-26, due to impact of Ind AS - 116.

Applications of funds: Fixed assets (gross) of the company increased by Rs 50.51% from Rs 522.79 crore as on March 31, 2025, to Rs 786.23 crore as on March 31, 2026, due to E Block, Solar project capitalisation and other capitalisation. Depreciation on tangible assets increased by Rs 40.85 % from Rs 19.56 crore in 2024-25 to Rs 27.55 crore in 2025-26 owing to increased capitalisation during the year.

Investments: Non-current investments of the company were Rs 63.24 crore in 2024-25, which increased to Rs 98.52 crore in 2025-26 on account of purchase of investments during the year.

Working capital management: Current assets of the company increased by 20.41% from Rs 442.07 crore as on March 31, 2025, to Rs 532.30 crore as on March 31, 2026, due to an increase in inventory and trade receivables. The current and quick ratios of the company stood at 4.40 and 2.69, respectively, at the close of 2025-26 compared to 5.32 and 3.88, respectively, at the close of 2024-25. Inventories, including raw materials, work-in-progress and finished goods, among others, increased by 34.85% from Rs 118.35 crore as on March 31, 2025, to Rs 159.60 crore as on March 31, 2026. The inventory cycle increased from 176 days of turnover equivalent in 2024-25 to 197 days of turnover equivalent in 2025-26. Trade receivables increased by 63.33% from Rs 134.36 crore as on March 31, 2025, to Rs 219.45 crore as on March 31, 2026, due to an increase in revenue during the year. 100% of the receivables were considered good. The company contained its debtor turnover cycle within 78 days of turnover equivalent in 2025-26, compared to 66 days in 2024-25. Loans and advances made by the company decreased by 38.60% from Rs 0.93 crore as on March 31, 2025, to Rs 0.57 crore as on March 31, 2026. Cash and bank balances of the company decreased by 0.36% from Rs 79.15 crore as on March 31, 2025, to Rs 78.87 crore as on March 31, 2026.

Margins: The EBITDA margin of the company for 2025-26 was 36.85% as against 38.85% in 2024-25, while the net profit for 2025-26 was 25.26% as against 26.61% in 2025-26. Typically, it takes three years for any new manufacturing block to reach peak capacity.

Key ratios

Particulars 2025-26 2024-25
EBITDA/Turnover (%) 36.85 38.85
EBITDA/Net interest ratio (x) 0.00 154.66
Debt-equity ratio (x) 0.00 0.01
Return on equity (%) 19.06 20.74
Book value per share (H) 148.82 123.85
Earnings per share (H) 25.98 23.35
Debtors Turnover (days) 78.00 66.00
Inventory Turnover (days) 197.00 176.00
Interest Coverage Ratio (x) 0.00 148.36
Current Ratio (x) 4.40 5.32
RMC Margin (%) 69.00 70.00
Operating Profit Margin (%) 32.96 35.42
Net Profit Margin (%) 24.91 26.61

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The internal control and risk management system is organised and employed in accordance with the principles and criteria set out in the corporate governance code of the organisation. It is an inherent part of the general organisational structure of Human Resources of the company and group and involves various persons to work and coordinate amongst each other to complete their respective duties. The board of directors provides various guidelines and supervises the strategy to the executive directors and management, monitoring and support committees. The risk management committee and the head of the audit department are supervised by the board-appointed statutory auditors.

HUMAN RESOURCES

The organisation holds the belief that its workforce plays a pivotal role in propelling business expansion. Throughout 2025-26, competitive compensation packages were offered, along with efforts to cultivate a positive work atmosphere and recognise employee achievements through a formal rewards system. The objective is to establish an environment where every employee can discover and maximise their capabilities. Alongside regular duties, participation in voluntary initiatives fostering learning and fostering creative thought is encouraged. The companys employee strength stood at 607 employees as of March 31, 2026.

CAUTIONARY STATEMENT

This statement made in this section describes the companys objectives, projections, expectation and estimations, which may be forward-looking statements within the meaning of applicable securities laws and regulations. Forward-looking statements are based on certain assumptions and expectations of future events. The company cannot guarantee that these assumptions and expectations are accurate or will be realised by the company. Actual results could differ materially from those expressed in the statement or implied due to the influence of external factors that are beyond the control of the company. The company assumes no responsibility to publicly amend, modify or revise any forward-looking statements on the basis of any subsequent development, information or events.

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited. All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.